Why It Matters

Generic drugmakers face a critical juncture as the FDA fast-tracks biosimilar approvals and the Trump administration pressures brand-name competitors through tariffs. The real bottleneck remains patent system abuse. The Association for Accessible Medicines (AAM) is lobbying to eliminate "pay-for-delay" settlements and "patent thickets" that artificially block competition—tactics that cost Medicare $9.9 billion between 2014-2023.

Legislative wins on bills like S.1096 and the PREVAIL Act would permanently weaken brand-name companies’ ability to delay cheaper alternatives. The challenge: convert bipartisan momentum and regulatory reforms into durable patent law changes before the legislative window closes.

By the Numbers

The Association for Accessible Medicines spent $640,000 on in-house lobbying in Q3 2025, part of over $50.7 million across 78 disclosures since 2003. AAM’s five-person team includes Mark Dale Ratner, a 22-year Republican congressional staffer with House Energy and Commerce experience, and Ilhaam A. Jaffer, a former Democratic deputy chief of staff.

The $640,000 Q3 expenditure targets patent reform, Medicare/Medicaid changes, and pharmacy cost controls—reflecting AAM’s consistent advocacy posture as a longstanding Capitol Hill player.

The Agenda

AAM is lobbying on specific legislation to increase generic and biosimilar competition. Key bills include the Preserve Access to Affordable Generics and Biosimilars Act targeting "pay-for-delay" settlements, the Biosimilar Red Tape Elimination Act to streamline approvals, and the PREVAIL Act for patent system reform.

The group is also pushing legislation addressing domestic pharmaceutical supply chains, country-of-origin labeling, and Medicare Part D reform.

Broader Context

AAM is lobbying amid dramatic policy realignment favoring generic competition. The FDA announced reforms in October 2025 to slash biosimilar approval timelines in half. The Trump administration deployed tariff threats on imported branded drugs while exempting generics—validating AAM’s domestic supply chain advocacy.

Congressional momentum is strong. Bipartisan coalitions are advancing multiple bills targeting "pay-for-delay" settlements. A bipartisan Senate report highlighted foreign pharmaceutical dependency risks, reframing AAM’s priorities as strategic imperatives.

Between The Lines

Congress is actively reshaping pharmaceutical policy in AAM’s favor. The Senate Judiciary Committee advanced bipartisan bills in April 2025 targeting "pay-for-delay" settlements—core AAM priorities. Senators Hassan, Paul, Hickenlooper, and Lee championed transparency measures for generic applications.

Key hearings amplified these themes. The House Energy and Commerce Committee examined domestic manufacturing incentives, while Ways and Means highlighted biosimilars’ $23.6 billion in cumulative savings.

Competitive Landscape

The generic industry presents a unified front beyond AAM. Viatris Inc. is pursuing an nearly identical 2025 lobbying slate, targeting the PREVAIL Act and FDA transparency measures. This coordination reflects industry-wide alignment on patent reform.

Senator Josh Hawley has specifically targeted "patent thickets" blocking biosimilar competition, while national security concerns from the Gillibrand-Scott report amplify AAM’s domestic manufacturing messaging.

The Bottom Line

AAM’s $640,000 Q3 spending aligns with bipartisan momentum to lower prescription costs through patent reform and FDA streamlining. The organization’s experienced team, led by congressional veterans like Ratner, is well-positioned to influence ongoing legislative efforts targeting "pay-for-delay" settlements and biosimilar barriers—areas where recent hearings indicate strong momentum.

Spot something wrong? Report an issue with this article